Supplementary tables from Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

Autor: Wei-Dong Han, Qing-Ming Yang, Su-Xia Li, Yang Liu, Kai-Chao Feng, Yan Zhang, Mei-Xia Chen, Wen-Ying Zhang, Ya-Jing Zhang, Xiang Li, Xiao-Hui Wang, Han-Ren Dai, Ye-Lei Guo, Yao Wang, Zhi-Qiang Wu, Chun-Meng Wang
Rok vydání: 2023
DOI: 10.1158/1078-0432.22466198.v1
Popis: Supplementary Table S1. Phonotypical characteristics of PBMCs and expanded T Cells as well as transduction efficiency of infused cell products. Supplementary Table S2. Detailed prior chemotherapy regimens for patients before CD30-CART treatment. Supplementary Table S3. Statistics of patient characteristics. Supplementary Table S4. The absolute doses of conditioning regimens for all enrolled patients. Supplementary Table S5. Toxicities possibly related to CD30-CART infusion-containing protocol. Supplementary Table S6. Maximum change from baseline of target measurable lesions. Supplementary Table S7. Clinical response in CD30-CAR T cell- treated patients.
Databáze: OpenAIRE